ESTRO 2024 - Abstract Book

S1427

Clinical - Head & neck

ESTRO 2024

1. Cho PS, Johnson RH, Griffin TW. Cone-beam CT for radiotherapy applications. Phys Med Biol. 1995; 40: 1863 1883.

2. Gao L, Xie K, Sun J, Lin T, Sui J, Yang G, Ni X. Streaking artifact reduction for CBCT-based synthetic CT generation in adaptive radiotherapy. Med Phys. 2023 Feb;50(2):879-893. doi: 10.1002/mp.16017. Epub 2022 Oct 18. PMID: 36183234.

2754

Digital Poster

Late patient reported toxicity outcomes for T1-2N0-1 hypopharynx carcinoma treated with IMRT/VMAT

John Gaffney 1,2 , Cliona Maley 3 , Deborah Ganderton 4 , Kate Garcez 1 , James Price 1 , David Thomson 1 , Lip Lee 1 , Christopher Hughes 1 , Andrew McPartlin 5 1 The Christie NHS Foundation Trust, Clincial Oncology, Manchester, United Kingdom. 2 University Hospital Galway, Radiation Oncology, Galway, Ireland. 3 The University of Edinburgh, Medical School, Edinburgh, United Kingdom. 4 The Christie NHS Foundation Trust, Speech & Language, Manchester, United Kingdom. 5 Princess Margaret Cancer Centre, Radiation Oncology, Toronto, Canada

Purpose/Objective:

Radical (chemo)radiotherapy ((CT)RT) is a standard of care for early hypopharyngeal cancer. Late patient reported outcomes (PROs) assessing late effects are poorly reported following treatment. We evaluate the long-term clinician and patient reported toxicity following (CT)RT for early hypopharyngeal cancer.

Material/Methods:

Prospectively maintained electronic patient records were used to retrospectively identify patients receiving curative modulated radiotherapy for T1-T2, N0-N1 hypopharyngeal carcinoma at a single academic oncology centre. Patients, disease and outcome specific data was captured and MD Anderson Dysphagia Inventory (MDADI) and University of Washington Quality of Life (UoF QoL) questionnaire was sent to those alive for completion.

Results:

Fifty-seven patients were identified. Patient characteristics are shown in table 1. Median progression free-survival was 20.6-months (range 1.1-85.7). Median overall-survival was 39.7-months (range 2.2-107.5). Eighteen (32%) developed local failure (LF), 5 (9%) regional failure and 6 (11%) distant failure (DF). Twenty-five (43.9%) patients were identified as alive and disease free at the time of follow up. Fourteen (56%) completed PRO questionnaires at a median of 59-months post treatment.

Two patients (14%) required enteral nutrition during or acutely after treatment. No patient required enteral support at last follow up. The main late (any grade) toxicities reported as most impactful in the previous 7 days were